How do TCR-Ts differ from CAR-T cell therapies?

T-cell receptor therapies (TCR-Ts) and chimeric antigen receptor T cell therapies (CAR-Ts) are created by engineering T cells. TCR-Ts are engineered to express a T-cell receptor that can recognise both extracellular and intracellular targets, including tumour-specific mutations expressed by cancer cells. CAR-Ts are genetically modified to express a chimeric antigen receptor that recognises a specific, cancer-associated protein on the surface of tumour cells.

We are advancing our diverse pipeline of innovative preclinical and clinical stage CAR-Ts and TCR-Ts across hard-to-treat tumours and malignancies.

Learn more about our ambition in cell therapy: https://www.astrazeneca.com/r-d/next-...

------------------------------------------------------------
Global site: https://www.astrazeneca.com/
Careers site: https://careers.astrazeneca.com/

Follow us:
Twitter:   / astrazeneca  
LinkedIn:   / astrazeneca  
Instagram:   / astrazeneca  
Facebook:   / astrazeneca